My Toolbox    |   Contact Us   |   Help    |   Sign In       

Home   |   Programs & Loans   |   Resources   |   Glossary   |   FAQs

  

Don't have an Account? Sign Up . It's Free

 Sign In to Your Account

E-mail Address* Password*
Forgot your Password?           * Required fields
    

 Why Sign Up for an Account?

Our tools will help you create a personalized business plan and financial statements. And all of it is free for everyone!

Business Plan

Use our easy, step-by-step form to generate your business plan. You can even use our sample business plan as a helpful guide.

Financial Reports

Answer the questions in our three step interview process and you will immediately be presented a Profit & Loss statement, and Cash Flow statement, and a Balance Sheet - all customized to your business.                               

Home

Sample Business Plan & Financial Reports

Your business plan is the road map for your business. It clearly defines your business, identifies your goals, and describes in detail where you are today, where you plan to be in the future, and how you are going to get there. Your business plan, like your business, is a living thing. No business remains static, the plan will need to be revisited periodically and updated to reflect changes in your business. Our website will save your plan for five years from the last time you visited it, unless you personally delete it. You can come back and edit it as often as you need.

View Sample


Industry News


FDA proposes ban on electrical stimulation devices intended to treat self-injurious or aggressive behavior 4/22/2016
The U.S. Food and Drug Administration today announced a proposal to ban electrical stimulation devices (ESDs) used for self-injurious or aggressive behavior because they present an unreasonable and substantial risk to public health that cannot be corrected or eliminated through changes to the labeling.
FDA launches first ad campaign focused on dangers of smokeless tobacco among rural teens 4/19/2016
The U.S. Food and Drug Administration announced today it is expanding its award-winning “The Real Cost” campaign to educate rural, white male teenagers about the negative health consequences associated with smokeless tobacco use. For the first time, messages on the dangers of smokeless tobacco use – including nicotine addiction, gum disease, tooth loss, and multiple kinds of cancer – are being highlighted through the placement of advertisements in 35 U.S. markets specifically selected to reach the campaign’s target audience.
FDA approves folic acid fortification of corn masa flour 4/14/2016
The U.S. Food and Drug Administration today approved folic acid fortification of corn masa flour. The approval allows manufacturers to voluntarily add up to 0.7 milligrams of folic acid per pound of corn masa flour, consistent with the levels of certain other enriched cereal grains.
FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality 4/11/2016
The U.S. Food and Drug Administration today approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with a least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL.
FDA takes steps to withdraw approval of the swine drug carbadox due to safety concerns 4/8/2016
Today, the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) took the first step toward rescinding its approval of the use of carbadox to treat swine because the drug may leave trace amounts of a carcinogenic residue.
FDA allows marketing of first-of-kind tissue containment system for use with certain laparoscopic power morcellators in select patients 4/7/2016
The U.S. Food and Drug Administration today permitted the marketing of PneumoLiner, the first tissue containment system for use with certain laparoscopic power morcellators to isolate uterine tissue that is not suspected to contain cancer. Although the device is an effective tissue containment system, the FDA is requiring the manufacturer to warn patients and health care providers that PneumoLiner has not been proven to reduce the risk of spreading cancer during these procedures.
FDA approves first leadless pacemaker to treat heart rhythm disorders 4/6/2016
The U.S. Food and Drug Administration today approved the first pacemaker that does not require the use of wired leads to provide an electrical connection between the pulse-generating device and the heart. While the Micra Transcatheter Pacing System works like other pacemakers to regulate heart rate, the self-contained, inch-long device is implanted directly in the right ventricle chamber of the heart.
FDA approves Inflectra, a biosimilar to Remicade 4/5/2016
The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.
FDA releases final rule to ensure food safety during transport 4/5/2016
The U.S. Food and Drug Administration today finalized a new food safety rule under the landmark FDA Food Safety Modernization Act (FSMA) that will help to prevent food contamination during transportation. The rule will require those involved in transporting human and animal food by motor or rail vehicle to follow recognized best practices for sanitary transportation, such as properly refrigerating food, adequately cleaning vehicles between loads and properly protecting food during transportation.
FDA proposes limit for inorganic arsenic in infant rice cereal 4/1/2016
The U.S. Food and Drug Administration is taking steps to reduce inorganic arsenic in infant rice cereal, a leading source of arsenic exposure in infants. Relative to body weight, rice intake for infants, primarily through infant rice cereal, is about three times greater than for adults. Moreover, national intake data show that people consume the most rice (relative to their weight) at approximately 8 months of age.
FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow 3/30/2016
The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT). This is the first FDA-approved therapy for treatment of severe hepatic VOD, a rare and life-threatening liver condition.
FDA allows use of investigational test to screen blood donations for Zika virus 3/30/2016
The U.S. Food and Drug Administration today announced the availability of an investigational test to screen blood donations for Zika virus. The screening test may be used under an investigational new drug application (IND) for screening donated blood in areas with active mosquito-borne transmission of Zika virus.
FDA takes important step to increase the development of, and access to, abuse-deterrent opioids 3/24/2016
The U.S. Food and Drug Administration today issued a draft guidance intended to support industry in their development of generic versions of approved opioids with abuse-deterrent formulations (ADF) while ensuring that generic ADF opioids are no less abuse-deterrent than the brand-name drug.
FDA approves Cinqair to treat severe asthma 3/23/2016
The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.
FDA approves new psoriasis drug Taltz 3/22/2016
The U.S. Food and Drug Administration today approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis.
FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death 3/22/2016
In a continuing effort to educate prescribers and patients about the potential risks related to opioid use, the U.S. Food and Drug Administration today announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. Today’s actions are among a number of steps the agency recently outlined in a plan to reassess its approach to opioid medications. The plan is focused on policies aimed at reversing the epidemic, while still providing patients in pain access to effective relief.
FDA proposes ban on most powdered medical gloves 3/21/2016
Today, the U.S. Food and Drug Administration announced a proposal to ban most powdered gloves in the United States. While use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness or injury to health care providers, patients and other individuals who are exposed to them, which cannot be corrected through new or updated labeling.
FDA approves new treatment for inhalation anthrax 3/21/2016
On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.
FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer 3/11/2016
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
FDA permits marketing of device that senses optimal time to check patient’s eye pressure 3/4/2016
The U.S. Food and Drug Administration today allowed marketing of a one-time use contact lens that may help practitioners identify the best time of day to measure a patient’s intraocular pressure (IOP). Elevated IOP is often associated with the optic nerve damage that is characteristic of glaucoma.

Loan Calculator
This is a quick way for you to find out how much it might cost you to buy that new piece of equipment or even a house. Simply enter your desired loan amount, term/period of loan and your estimated percentage rate to calculate your likely monthly payment.

 Loan  Amount: $*  
 Terms in  Months: *  
 Interest  Rate:*  %
 

 

* Required fields


Programs and Loans [more]
Our Business Plans and Financial Reports are designed to be taken to any bank or lender and there are many programs available in the agricultural industry. Find a program or lender that is right for you today.

Resources [more]
We have provided links to useful resources. Please click on "more" to access them. You may also access these links after you have logged in by clicking on Resources located at the top of each page.

 

Privacy Statement   |   Contact Us